Investor Presentaiton

Immunology LPA₁ Sotyktu CD19 NEX T Severe, refractory SLE Phase 1 study Open label1: Assess the safety, preliminary efficacy, pharmokinetics Key eligibility criteria: 2019 ACR/EULAR classification criteria of SLE Presence of anti-dsDNA, anti-histone, anti-chromatin, or anti-Sm antibodies • ≥ 1 major organ system with a BILAG A score Inadequate response to glucocorticoids and to at least 2 treatments Part A Dose escalation Part B Dose expansion to optimize RP2D Data anticipated in 2024 Ill Bristol Myers Squibb™ 1. NCT05869955 Not for Product Promotional Use 70

View entire presentation